BioMarin Pharma (BMRN)
56.77
+0.30 (0.53%)
Upcoming Events
Latest Headlines
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: Countouriotis Athena
June 4, 2026 6:10 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: Walbert Timothy P
June 4, 2026 6:09 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: Ho Maykin
June 4, 2026 6:08 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: HOMBACH ROBERT J.
June 4, 2026 6:07 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: Enyedy Mark J
June 4, 2026 6:06 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: Dere Willard H
June 4, 2026 6:05 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: CLARK IAN T
June 4, 2026 6:04 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: Bodem Barbara W.
June 4, 2026 6:03 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Jun 02 Filed by: ANDERSON ELIZABETH M
June 4, 2026 6:02 PM - SEC Filing
Form 8-K BIOMARIN PHARMACEUTICAL For: Jun 02
June 4, 2026 4:24 PM - SEC Filing
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
May 28, 2026 4:07 PM - StreetInsider
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
May 22, 2026 6:51 AM - StreetInsider
Form 4 BIOMARIN PHARMACEUTICAL For: May 20 Filed by: Hubbard Cristin
May 21, 2026 6:05 PM - SEC Filing
BioMarin reports positive phase 3 trial results for VOXZOGO in hypochondroplasia
May 20, 2026 4:20 PM - StreetInsider
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
May 20, 2026 4:20 PM - PR NewsWire
JPMorgan Reinstates BioMarin Pharmaceutical Inc. (BMRN) at Overweight
May 20, 2026 4:30 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $50 at H.C. Wainwright
May 19, 2026 6:46 AM - StreetInsider
Citi Starts BioMarin Pharmaceutical Inc. (BMRN) at Buy
May 18, 2026 4:14 PM - StreetInsider
BioMarin drug trial meets one of two primary goals in rare disease study
May 18, 2026 9:05 AM - StreetInsider
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
May 18, 2026 9:05 AM - PR NewsWire
Form 4 BIOMARIN PHARMACEUTICAL For: May 07 Filed by: Friberg Gregory R
May 11, 2026 5:01 PM - SEC Filing
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $110 at Freedom Broker
May 11, 2026 11:31 AM - StreetInsider
Goldman Sachs Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral
May 11, 2026 5:18 AM - StreetInsider
Form 144 BIOMARIN PHARMACEUTICAL Filed by: Friberg Gregory R
May 7, 2026 1:18 PM - SEC Filing
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $116 at Canaccord
May 7, 2026 6:38 AM - StreetInsider
Form 10-Q BIOMARIN PHARMACEUTICAL For: Mar 31
May 5, 2026 2:00 PM - SEC Filing
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $119 at Morgan Stanley
May 5, 2026 8:00 AM - StreetInsider
4D Path raises funds, adds Katherine Vega Stultz and Robert Hombach to board
May 5, 2026 7:00 AM - StreetInsider
4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors
May 5, 2026 7:00 AM - BizWire
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $82 at Bernstein SocGen Group
May 5, 2026 6:00 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $120 at Evercore ISI
May 5, 2026 4:15 AM - StreetInsider
BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
May 4, 2026 4:10 PM - StreetInsider
Form 8-K BIOMARIN PHARMACEUTICAL For: May 04
May 4, 2026 4:08 PM - SEC Filing
BioMarin Reports First Quarter 2026 Financial and Operating Results
May 4, 2026 4:05 PM - PR NewsWire
BioMarin shares VOXZOGO data showing bone health benefits in children
May 4, 2026 5:54 AM - StreetInsider
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 202
May 2, 2026 3:30 PM - PR NewsWire
Form SCHEDULE 13G BIOMARIN PHARMACEUTICAL Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 5:08 PM - SEC Filing
Form 8-K BIOMARIN PHARMACEUTICAL For: Apr 27
April 27, 2026 8:45 AM - SEC Filing
BioMarin completes $4.8 billion acquisition of Amicus Therapeutics
April 27, 2026 8:44 AM - StreetInsider
BioMarin Completes Acquisition of Amicus Therapeutics
April 27, 2026 8:44 AM - PR NewsWire
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
April 27, 2026 7:30 AM - PR NewsWire
Morgan Stanley Resumes BioMarin Pharmaceutical Inc. (BMRN) at Overweight
April 27, 2026 6:19 AM - StreetInsider
Form 8-K BIOMARIN PHARMACEUTICAL For: Apr 23
April 23, 2026 7:10 PM - SEC Filing
BioMarin appoints Ian Clark as board chair, Richard Meier to retire
April 21, 2026 4:24 PM - StreetInsider
BioMarin Announces Board Leadership Transition
April 21, 2026 4:24 PM - PR NewsWire
Form ARS BIOMARIN PHARMACEUTICAL For: Dec 31
April 21, 2026 4:23 PM - SEC Filing
Form DEFA14A BIOMARIN PHARMACEUTICAL
April 21, 2026 4:22 PM - SEC Filing
Form DEF 14A BIOMARIN PHARMACEUTICAL For: Jun 02
April 21, 2026 4:20 PM - SEC Filing
Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VANGUARD GROUP INC
March 26, 2026 4:10 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 18 Filed by: Davis George Eric
March 19, 2026 4:53 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Guyer Charles Greg
March 19, 2026 4:51 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Mueller Brian
March 19, 2026 4:49 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Hardy Alexander
March 19, 2026 4:34 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Hubbard Cristin
March 18, 2026 1:42 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Friberg Gregory R
March 18, 2026 1:40 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: Guyer Charles Greg
March 17, 2026 8:51 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Davis George Eric
March 17, 2026 8:48 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: Mueller Brian
March 17, 2026 8:46 PM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: Hardy Alexander
March 17, 2026 8:43 PM - SEC Filing
Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN): 'we'd be buyer on weakness'
March 16, 2026 10:07 AM - StreetInsider
Form 8-K BIOMARIN PHARMACEUTICAL For: Mar 16
March 16, 2026 8:31 AM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 11 Filed by: Guyer Charles Greg
March 12, 2026 7:56 PM - SEC Filing
Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign"
March 12, 2026 9:26 AM - StreetInsider
BioMarin reports early VOXZOGO treatment benefits for achondroplasia
March 12, 2026 9:05 AM - StreetInsider
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical
March 12, 2026 9:05 AM - PR NewsWire
Form 144 BIOMARIN PHARMACEUTICAL Filed by: Guyer Charles Greg
March 11, 2026 3:23 PM - SEC Filing
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $85 at BofA Securities
March 11, 2026 5:18 AM - StreetInsider
Leerink on BioMarin Pharma (BMRN): 'We continue to hold a more cautious view on the outlook for Voxzogo'
March 9, 2026 2:38 PM - StreetInsider
Full Article List
